Janus kinase inhibitors

Overview

Janus kinase inhibitors (JAK inhibitors, or JAKis) are a class of targeted anti-inflammatory and immunomodulatory therapies that block signaling through the Janus kinase–signal transducer and activator of transcription (JAK-STAT) pathway. The Janus kinase family comprises four members — JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2) — which associate with cytokine receptors and phosphorylate STAT transcription factors; individual inhibitors differ in which of these kinases they preferentially block, and that selectivity shapes both their efficacy and their adverse-effect profiles. By suppressing JAK-mediated cytokine signaling, these agents reduce immune activation across a range of inflammatory, autoimmune, and myeloproliferative diseases, including rheumatoid arthritis, atopic dermatitis, alopecia areata, systemic sclerosis, scleritis, drug reaction with eosinophilia and systemic symptoms (DRESS), and myelofibrosis.

Agents in this class include the pan-JAK inhibitor tofacitinib, the JAK1/2 inhibitors baricitinib and ruxolitinib (the latter a mainstay of myelofibrosis therapy), and the more JAK1-selective agents upadacitinib and abrocitinib. Despite differing in selectivity and approved indications, they share the same core principle of suppressing cytokine-driven inflammation. Because JAK signaling is broadly involved in immune and hematopoietic pathways, the class carries a regulatory boxed warning for serious adverse events — including major adverse cardiovascular events, venous thromboembolism, malignancy, and serious infection — so the balance of efficacy, safety, and patient-reported outcomes remains a central focus of ongoing research.

Focus of Latest Publications

Recent publications on Janus kinase inhibitors have focused heavily on real-world effectiveness, safety, and treatment optimization across multiple immune-mediated diseases. In rheumatoid arthritis, one study set out to compare sarilumab with Janus kinase inhibitors in late-onset and younger-onset disease, reflecting ongoing interest in glucocorticoid- and methotrexate-sparing strategies. In systemic sclerosis, a multicenter real-life study evaluated longitudinal changes in pulmonary, articular, and cutaneous parameters among patients treated with Janus kinase inhibitors, underscoring their emerging use across multiple clinical domains.

Several recent studies examined Janus kinase inhibitors in dermatologic disease. In alopecia areata, a retrospective cohort study of patients treated with tofacitinib or ritlecitinib found better week-24 outcomes in acute versus non-acute disease, with acute cases more often achieving SALT100 and tofacitinib identified as a predictor of super-responder status. Another publication used a discrete choice experiment to assess patient preferences for treatment characteristics of Janus kinase inhibitors in alopecia areata, while a multinational cohort study in skin immune-mediated inflammatory diseases compared Janus kinase inhibitors with conventional immunomodulators and found no increase in mortality, major adverse cardiovascular events, venous thromboembolism, or malignancy over 2 years.

In inflammatory bowel disease, a multicenter retrospective cohort study in ulcerative colitis evaluated whether concomitant 5-aminosalicylic acid, including mesalazine, affected outcomes during treatment with tofacitinib, upadacitinib, or filgotinib. Clinical remission at week 48 was similar with and without 5-ASA, and the adjusted analysis found no significant effect on time to remission. Another retrospective study addressed flare characteristics in atopic dermatitis patients receiving Janus kinase inhibitors, highlighting that real-world flare incidence, presentation, predictors, and management remain insufficiently characterized outside randomized trials.

Other recent publications extended Janus kinase inhibitor research into hematologic malignancy and severe inflammatory syndromes. A Japanese real-world study in myelofibrosis described treatment patterns and outcomes in patients receiving ruxolitinib, the only Janus kinase inhibitor used in that cohort, with detailed reporting of anemia, thrombocytopenia, transfusion burden, and survival. In refractory drug reaction with eosinophilia and systemic symptoms, a small case series reported rapid clinical improvement and successful corticosteroid tapering with baricitinib or abrocitinib, alongside reductions in cytokines such as interleukin-5. Janus kinase inhibition has also been discussed in the context of severe immune-related adverse events from checkpoint inhibitor therapy, where a rapid response highlighted reported remission activity and the need to better define safety and the balance between irAE control and antitumor immunity.

Key Publications

• NEWJun Comparative effectiveness and safety of sarilumab vs Janus kinase inhibitors in late- and younger-onset rheumatoid arthritis. (Rheumatology (Oxford, England), 2026, PMID 42261260): "This study aimed to compare the effectiveness and safety of sarilumab and JAK inhibitors in patients with late- and younger-onset rheumatoid arthritis."
• Jun Longitudinal clinical response to Janus kinase inhibitors in systemic sclerosis: a real-life multicentric study across multiple clinical domains. (Clinical rheumatology, 2026, PMID 42217099): "Janus kinase inhibitors (JAKi's) have shown promising results in systemic sclerosis (SSc), yet little studied."
• May Comparative Efficacy of JAK Inhibitors in Acute vs Nonacute Alopecia Areata: A Retrospective Cohort Study. (Acta dermato-venereologica, 2026, PMID 42186168): "...the efficacy of Janus kinase (JAK) inhibitors in acute versus non-acute alopecia areata (AA) remains poorly defined..."
• May Patient preferences for treatment characteristics of Janus kinase inhibitors for alopecia areata: a discrete choice experiment. (The Journal of dermatological treatment, 2026, PMID 42138161): "Janus kinase inhibitors (JAKis) can improve hair regrowth in alopecia areata (AA)."
• May A 52-Week Retrospective Italian Study of Flare Characteristics in Adult Atopic Dermatitis Patients Receiving JAK Inhibitors. (International journal of dermatology, 2026, PMID 42138359): "Atopic dermatitis (AD) flares occurring during treatment with Janus kinase inhibitors (JAKi) remain insufficiently characterized outside randomized clinical trials."
• May Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan. (PloS one, 2026, PMID 42102170): "This longitudinal, retrospective, and descriptive cohort study used a Japanese health administrative database (Medical Data Vision) to examine treatment patterns, transfusion burden, healthcare resource utilization, and costs in patients with myelofibrosis and a subset treated with a Janus kinase inhibitor."
• Apr Rapid response: Context-dependent immunomodulatory effects of JAK inhibition in the management of severe immune-related adverse events. (Journal for immunotherapy of cancer, 2026, PMID 42031428): "Recent studies have indicated that Janus kinase inhibitors (JAKi) exert context-dependent immunomodulatory effects in cancer immunotherapy."
• Jun Real-World Safety of JAK Inhibitors in Skin Immune-Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study. (Clinical pharmacology and therapeutics, 2026, PMID 41830903): "Janus kinase inhibitors (JAKis) have emerged as effective treatments for several skin immune-mediated inflammatory diseases (IMIDs)."
• Mar Concomitant 5-Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis. (Clinical pharmacology and therapeutics, 2026, PMID 41786642): "We evaluated whether concomitant 5-aminosalicylic acid (5-ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi)."
• May Janus kinase 1 and 1/2 inhibitors for treating drug reaction with eosinophilia and systemic symptoms: a case series. (Clinical and experimental dermatology, 2026, PMID 41652871): "In this retrospective single-centre case series, we evaluated the effectiveness and safety of selective Janus kinase (JAK) inhibitors in facilitating CS tapering in patients with moderate-to-severe refractory DRESS and in ameliorating pruritus."